Healthcare Industry News: kidney disease
News Release - September 10, 2009
Ritter Pharmaceuticals Hires Dr. Howard Foyt as Executive Vice President, Development & Chief Medical OfficerLOS ANGELES, Sept. 10 -- (Healthcare Sales & Marketing Network) -- Ritter Pharmaceuticals, Inc. (Ritter) has hired Howard Foyt, M.D., Ph.D., FACP as its new Executive VP, Development & Chief Medical Officer. Dr. Foyt brings 13 years of expertise in drug development to Ritter, as the Company prepares to file an IND for its therapy for Lactose Intolerance.
Dr. Foyt will join Ritter's senior management team and oversee the Company's clinical development efforts. Ritter will take advantage of Dr. Foyt's leadership in drug development within big pharma and biotech companies. For the past three years, Dr. Foyt served as VP, Clinical Development and Chief Medical Officer at Metabasis Therapeutics, where he was responsible for five drugs in clinical development over multiple therapeutic areas. Dr. Foyt had previously worked at Pfizer, where he served as Senior Director and Site Head - Diabetes & Obesity, and earlier at Parke-Davis for over ten years participating in the clinical development of multiple drugs mainly in the metabolic disease field. Prior to joining Parke-Davis, Dr. Foyt was on the faculty at the University of Texas Medical Branch, Galveston, TX. He earned his medical degree and Ph.D. in Cell Biology from Baylor College of Medicine. Dr. Foyt completed his residency in internal medicine at Baylor and an endocrinology fellowship at the National Institute of Diabetes and Digestive and kidney diseases, National Institutes of Health.
"We are thrilled to have Dr. Foyt on our team," said Ritter Pharmaceuticals' President and CEO Andrew Ritter. "His breadth of clinical development and drug development experience will bring a great deal of scientific rigor and creativity to our development plans."
About Ritter Pharmaceuticals
Ritter is committed to the discovery, development and commercialization of innovative therapies for gastrointestinal diseases. The Company's scientific platform of gastrointestinal physiology, metabolism and gut adaptation brings creativity to providing unique therapeutic approaches to a variety of GI diseases, including lactose intolerance, irritable bowel syndrome, Crohn's disease, and ulcerative colitis. Ritter's ultimate goal is to improve digestive health and overall quality of life.
Ritter's first compound, RP-G28, has been developed for the treatment of lactose intolerance. RP-G28 will effectively stand out as the first FDA-approved drug for the treatment of lactose intolerance.
Source: Ritter Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.